Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces regulatory filing of Saroglitazar Magnesium for treatment of NASH with DCGI

Posted On: 2019-12-06 13:36:40


Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has filed the NDA of Saroglitazar Mg in Non-alcoholic Steatohepatitis (NASH) with the Drug Controller General of India (DCGI).

NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatment of NASH. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure.

"There is a significant need for new therapies for patients with NASH, who have no treatment options as their liver disease progresses, other than opting for eventual liver transplants to survive" said Pankaj R. Patel, Chairman, Zydus group said, "We are very pleased that our NDA filing has been accepted for review which we believe represents an important step towards providing an innovative treatment option for millions of patients suffering from this devastating liver disease."

Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvement in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in Phase II clinical trials.

Zydus had also achieved positive results in EVIDENCES II Phase 3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint evaluated the histological improvement of NASH using liver biopsy at the end of 52 weeks. Separately, the results of EVIDENCES IV trial of Saroglitazar Mg in patients with NASH were presented as a Late Breaker at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.256.65 as compared to the previous close of Rs. 263.35. The total number of shares traded during the day was 27733 in over 517 trades.

The stock hit an intraday high of Rs. 264 and intraday low of 256.65. The net turnover during the day was Rs. 7223917.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Abbott India Ltd posts Rs. 180.35 crore PAT in Q1FY21

FDC Limited to acquire further stake in South Africa firm

Energy Development Company Ltd board recommends dividend of Rs. 0.50

Hero MotoCorp donates unique first responder vehicles to Civil Hospital, Gurugram

Mirchi revenues fall 72%, but market share rises to 33%

FDC Ltd board approves buy-back at Rs. 450

Gujarat Themis Biosyn Ltd board to approve quarterly results on Aug 13, 2020

Ravileela Granites Ltd Q1 consolidated net profit up at Rs. 0.74 crore

Indowind Energy Ltd posts consolidated PAT of Rs. 3.40 crore in Q1

FDC Ltd reports consolidated PAT of Rs. 91.72 crore in Q1FY21

Mercury Laboratories Ltd Q1 PAT at Rs. 0.96 crore

BATA India Ltd reports loss of Rs. 100.88 crore in Q1FY21

Seshasayee Paper & Boards Ltd Q1FY21 consolidated net profit lower at Rs. 19.30 crore

ANUH Pharma Ltd board approves 1:1 bonus issue

Siemens Limited announces Q3 FY 2020 results, Performance impacted due to COVID-19

WINTAC Ltd Q1 loss at Rs. 0.3158 crore

Sudarshan Chemical Industries Ltd posts Rs. 18.19 crore consolidated PAT in Q1FY21

CIPLA Ltd Q1FY21 consolidated PAT up at Rs. 577.91 crore

DIC India Ltd Q2CY20 PAT soars on exceptional income

Andhra Paper Ltd reports loss in Q1FY21

Natural Capsules Ltd Q1FY21 net profit surges to Rs. 2.48 crore

The Shipping Corporation of India Ltd posts consolidated PAT of Rs. 336.87 crore in Q1FY21

ANUH Pharma Ltd Q1FY21 net profit up at Rs. 16.72 crore

RAMCO Industries Ltd Q1FY21 consolidated net profit rises to Rs. 61.83 crore

Container Corporation of India Ltd Q1FY21 consolidated PAT slides to Rs. 60.61 crore

Automotive Axles Ltd Q1 loss at Rs. 2.30 crore

Morganite Crucible India Ltd posts loss of Rs. 0.67 crore in Q1

Monte Carlo Fashions Ltd Q1FY21 loss at Rs. 13.53 crore

Nucleus Software Exports Ltd Q1FY21 consolidated PAT surges to Rs. 36.33 crore

Kesar Enterprises Ltd Q4FY20 PAT surges to Rs. 36.90 crore

Murugappa group firm to invest in CG Power and Industrial Solutions Ltd

Zensar to host Digital Foundation Services (DFS) Virtual Analyst and Advisor Conclave

JK Agri Genetics Ltd to raise funds upto Rs. 50 crore

Apollo Hopsital asks for 50% rent waiver

Shree Renuka Sugars Ltd to issue 2,11,670,481 Equity Shares at Rs. 8.74

REC Ltd Q1FY21 consolidated PAT soars to Rs. 1845.30 crore

Amara Raja Batteries Ltd Q1FY21 consolidated net profit declines to Rs. 62.49 crore

Aditya Birla Capital Ltd Q1FY21 consolidated net profit at Rs. 198.38 crore

Mangalam Cement Ltd posts net profit of Rs. 13.79 crore in Q1

Kaycee Industries Ltd Q1 loss at Rs. 0.20 crore

Nath Bio-Genes India Ltd Q1FY21 PAT rises to Rs. 41.25 crore

Birla Corporation Ltd reports earnings for Q1FY21

JK Agri Genetics Ltd Q1 PAT zooms to Rs. 19.20 crore

Finolex Industries Ltd posts consolidated PAT of Rs. 56.72 crore in Q1FY21

Shreyans Industries Ltd posts Rs. 6.77 crore PAT in Q1

Adani Transmission Ltd Q1FY21 consolidated PAT higher at Rs. 383.55 crore

Targeting the significant shift to Spiritual-Religious Tourism, Thomas Cook India & SOTC launch Ramayana Trails

Rane Madras Ltd announces Q1FY21 results

BHEL commences Civil Works at 660 MW Sagardighi Supercritical Thermal Power Plant in West Bengal

Equitas Small Finance Bank Limited is now the official retail banking partner of Chennai Super Kings







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019